Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 1/2024

Open Access 07-11-2023 | Breast Cancer | Special Article

The Japanese breast cancer society clinical practice guidelines for pathological diagnosis of breast cancer, 2022 edition

Authors: Naoko Honma, Masayuki Yoshida, Keiichi Kinowaki, Rie Horii, Yuka Katsurada, Yuya Murata, Ai Shimizu, Yuko Tanabe, Chikako Yamauchi, Yutaka Yamamoto, Hiroji Iwata, Shigehira Saji

Published in: Breast Cancer | Issue 1/2024

Login to get access

Excerpt

This article is an English digest of the guidelines for pathological diagnosis published in The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines in Japanese by Kanehara & Co., Ltd. in July 2022. In the 2022 edition, six Reviews, eight Basic Questions (BQs), and six Future Research Questions (FRQs) were included. Unlike for other fields, no Clinical Question (CQ) was included because an interventional study is rarely performed in diagnostic pathology. BQs refer to routinely used pathological methods supported by extensive evidence. The BQs for human epidermal growth factor receptor 2 (HER2) and hormone receptors have been revised according to revised international guidelines. FRQs refer to relatively new areas or non-routine methods supported by less evidence. Two new FRQs have been established for PD-L1 and cancer gene panel testing. …
Literature
1.
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26:1533–46.CrossRefPubMedPubMedCentral
2.
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al. (2017) De-escalating and escalating treatments for early-stage breast cancer: the St Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 28:1700–12
3.
Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, et al. (2021) Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 32:1216–35
4.
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020;38:1346–66.CrossRefPubMed
5.
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36:2105–22.CrossRefPubMed
6.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–10.CrossRefPubMed
7.
Tsuda H, Akiyama F, Kurosumi M, Sakamoto G, Watanabe T. Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section. Jpn J Clin Oncol. 1998;28:486–91.CrossRefPubMed
8.
Anonymous (2019) WHO classification of Tumours, 5th ed., Vol.2. Breast Tumours. Lyon: International Agency for Research on Cancer
9.
Elmore JG, Longton GM, Carney PA, Geller BM, Onega T, Tosteson ANA, et al. Diagnostic concordance among pathologists interpreting breast biopsy specimens. JAMA. 2015;313:1122–32.CrossRefPubMedPubMedCentral
10.
Lacroix-Triki M, Mery E, Voigt J, Istier L, Rochaix P. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody. Virchows Arch. 2003;442:548–54.CrossRefPubMed
11.
Otterbach F, Bànkfalvi A, Bergner S, Decker T, Krech R, Boecker W. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology. 2000;37:232–40.CrossRefPubMed
12.
Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP. Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol. 1999;188:237–44.CrossRefPubMed
13.
Grin A, O’Malley FP, Mulligan AM. Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy. Am J Surg Pathol. 2009;33:1615–23.CrossRefPubMed
14.
Nash JW, Morrison C, Frankel WL. The utility of estrogen receptor and progesterone receptor immunohistochemistry in the distinction of metastatic breast carcinoma from other tumors in the liver. Arch Pathol Lab Med. 2003;127:1591–5.CrossRefPubMed
15.
Kandalaft PL, Simon RA, Isacson C, Gown AM. Comparative Sensitivities and Specificities of Antibodies to Breast Markers GCDFP-15, Mammaglobin A, and Different Clones of Antibodies to GATA-3: A Study of 338 Tumors Using Whole Sections. Appl Immunohistochem Mol Morphol. 2016;24:609–14.CrossRefPubMed
16.
Na K, Lee J, Sung J, Kim GM, Koo JS, Kim H. Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma. Virchows Arch. 2018;473:165–75.CrossRefPubMed
17.
Yamaguchi R, Tsuchiya S, Koshikawa T, Ishihara A, Masuda S, Maeda I, et al. Diagnostic accuracy of fine-needle aspiration cytology of the breast in Japan: report from the Working Group on the Accuracy of Breast Fine-Needle Aspiration Cytology of the Japanese Society of Clinical Cytology. Oncol Rep. 2012;28:1606–12.CrossRefPubMed
18.
Pisano ED, Fajardo LL, Caudry DJ, Sneige N, Frable WJ, Berg WA, et al. Fine-needle aspiration biopsy of nonpalpable breast lesions in a multicenter clinical trial: results from the radiologic diagnostic oncology group V. Radiology. 2001;219:785–92.CrossRefPubMed
19.
Mukai H, Arihiro K, Shimizu C, Masuda N, Miyagi Y, Yamaguchi T, et al. Stratifying the outcome after neoadjuvant treatment using pathological response classification by the Japanese Breast Cancer Society. Breast Cancer. 2016;23:73–7.CrossRefPubMed
20.
Yamaguchi T, Mukai H, Akiyama F, Arihiro K, Masuda S, Kurosumi M, et al. Inter-observer agreement among pathologists in grading the pathological response to neoadjuvant chemotherapy in breast cancer. Breast Cancer. 2018;25:118–25.CrossRefPubMed
21.
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72.CrossRefPubMed
22.
von Minckwitz G, Untch M, Blohmer J, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796–804.CrossRef
23.
Umemura S, Kurosumi M, Moriya T, Oyama T, Arihiro K, Yamashita H, et al. Immunohistochemical evaluation for hormone receptors in breast cancer: a practically useful evaluation system and handling protocol. Breast Cancer. 2006;13:232.CrossRefPubMed
24.
Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474–81.CrossRefPubMed
25.
Hattori M, Honma N, Nagai S, Narui K, Shigechi T, Ozaki Y, et al. Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Low Advanced or Metastatic Breast Cancer: Recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines. Breast Cancer in press
26.
Vos EL, Siesling S, Baaijens MHA, Verhoef C, Jager A, Voogd AC, et al. Omitting re-excision for focally positive margins after breast-conserving surgery does not impair disease-free and overall survival. Breast Cancer Res Treat. 2017;164:157–67.CrossRefPubMedPubMedCentral
27.
Jobsen JJ, Van Der Palen J, Ong F, Meerwaldt JH. Differences in outcome for positive margins in a large cohort of breast cancer patients treated with breast-conserving therapy. Acta Oncol. 2007;46:172–80.CrossRefPubMed
28.
Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T, Iwase T, Akiyama F, et al. One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res. 2007;13:4807–16.CrossRefPubMed
29.
Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 2011;306:385–93.CrossRefPubMedPubMedCentral
30.
Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet. 1995;345:1154–7.CrossRefPubMed
31.
Anonymous (1997) Consensus Conference on the classification of ductal carcinoma in situ The Consensus Conference Committee. Cancer 80:1798–802
32.
Van de Ven S, Smit VTHBM, Dekker TJA, Nortier JWR, Kroep JR. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev. 2011;37:422–30.PubMed
33.
Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske A, et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS ONE. 2012;7: e37379.CrossRefPubMedPubMedCentral
34.
Vohra P, Buelow B, Chen Y, Serrano M, Vohra MS, Berry A, et al. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study. Cancer Cytopathol. 2016;124:828–35.CrossRefPubMed
35.
Shield PW, Papadimos DJ, Walsh MD. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens. Cancer Cytopathol. 2014;122:307–12.CrossRefPubMed
36.
Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol. 2013;31:860–7.CrossRefPubMed
37.
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259–71.CrossRefPubMed
38.
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817–28.CrossRefPubMed
39.
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379:2108–21.CrossRefPubMed
40.
Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, et al. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. J Natl Cancer Inst. 2021;113:1733–43.CrossRefPubMedPubMedCentral
41.
Naito Y, Aburatani H, Amano T, Baba E, Furukawa T, Hayashida T, et al. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). Int J Clin Oncol. 2021;26:233–83.CrossRefPubMed
Metadata
Title
The Japanese breast cancer society clinical practice guidelines for pathological diagnosis of breast cancer, 2022 edition
Authors
Naoko Honma
Masayuki Yoshida
Keiichi Kinowaki
Rie Horii
Yuka Katsurada
Yuya Murata
Ai Shimizu
Yuko Tanabe
Chikako Yamauchi
Yutaka Yamamoto
Hiroji Iwata
Shigehira Saji
Publication date
07-11-2023
Publisher
Springer Nature Singapore
Published in
Breast Cancer / Issue 1/2024
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-023-01518-6

Other articles of this Issue 1/2024

Breast Cancer 1/2024 Go to the issue

Review Article

Rethinking screening mammography in Japan: next-generation breast cancer screening through breast awareness and supplemental ultrasonography

Special Article

The Japanese Breast Cancer Society Clinical Practice Guidelines for surgical treatment of breast cancer, 2022 edition

Original Article

Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole

Special Article

Annual report of the Japanese Breast Cancer Registry for 2019

Original Article

Psychometric evaluation of the Chinese version of the breast cancer perception scale for community women: a translation and validation study

Original Article

Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits